Rodabe N Amaria, MD
UT MD Anderson · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rodabe N Amaria, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07511036 · PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaM.D. Anderson Cancer Center · not yet recruiting · Melanoma · principal investigator
- Ph1/Ph2NCT06598371 · A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid TumorsM.D. Anderson Cancer Center · recruiting · Select Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT06237881 · A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid TumorsM.D. Anderson Cancer Center · active not recruiting · Advanced Solid Tumor, Melanoma, Lung Neoplasms · principal investigator
- Ph1NCT05470283 · Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic MelanomaM.D. Anderson Cancer Center · active not recruiting · Tumor, Metastatic Melanoma, Melanoma · principal investigator
- Ph1/Ph2NCT02225366 · Intratumoral Injections of LL37 for MelanomaM.D. Anderson Cancer Center · completed · Melanoma · principal investigator
- Ph1NCT01603212 · Systemic Therapy With Interferon, Interleukin-2 and BRAF InhibitorM.D. Anderson Cancer Center · completed · Melanoma · principal investigator
- Ph1NCT01409174 · IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaM.D. Anderson Cancer Center · terminated · Melanoma · principal investigator
- Ph1NCT01067066 · A Phase I Study of TPI 287 - Temozolomide Combination in MelanomaM.D. Anderson Cancer Center · terminated · Melanoma · study chair
- Ph1NCT01039844 · Study of Weekly LOC-paclitaxel Injection for MelanomaM.D. Anderson Cancer Center · terminated · Melanoma · principal investigator
- Ph2NCT00338377 · Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaM.D. Anderson Cancer Center · active not recruiting · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The University of Texas M. D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ELIZABETH A GRIMM · fiscal years 2004 to 2014Named on NCT02225366
- The role of the PI3K pathway in immune resistanceR01CA187076 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, PATRICK HWU · fiscal years 2014 to 2018Named on NCT00338377
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.